Participants 83 144 3
Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia
Participants 365 447 6
evaluated in a large number of human volunteers in India, Vietnam, and Bangladesh,
Participants 585 696 10
in Ethiopia, where we evaluated the safety and immunogenicity of the vaccine in 216 healthy adults and children
Participants 801 898 3
81% adults and 77% children demonstrating seroconversion 14 days after the second dose of vaccine
